[Originating GP surgery’s letterhead/logo/address details]

Mrs/Miss/Ms [add patient’s name]

[Address line 1]

[Address line 2]

[Address line 3]

[Address line 4]

[add date]

Dear Mrs/Miss/Ms [add patient’s name],

**Reminder: the name of your oral contraceptive has changed from:**

**Mercilon®** (20 mcg ethinylestradiol + 150 mcg desogestrel)

**To:**

**Bimizza®** (20 mcg ethinylestradiol + 150 mcg desogestrel)

Bimizza® contains the **same active ingredients in the same amounts** as Mercilon®,and is therefore considered to **work in the same way.1–3**

Please continue to take Mercilon® until you run out of tablets. As Bimizza® is the same strength as Mercilon®, after your normal ‘pill-free’ interval, simply start taking Bimizza® in the same way you took Mercilon®.1,2

Your Bimizza® pack will contain a Patient Information Leaflet, which will answer many of the questions you may have about your new brand of pill. You can also find out about Bimizza® at: [www.morningsidecontraceptives.com](http://www.morningsidecontraceptives.com). Simply go the website, click on ‘*I have been prescribed a Morningside Contraceptive’* and then select ‘*view more*’ under Bimizza®.

Changing to Bimizza® is as simple as getting used to the new packaging – you’ll take the same number of tablets each month, and request repeat prescriptions in the same way as when you took Mercilon®.1,2 When taken correctly, Bimizza® is just as effective at preventing pregnancy as Mercilon®.3 However, if you wish to discuss this change, please arrange to speak with one of our GPs or our Family Planning Nurse.

Yours sincerely,

Dr [add name]

Dr [add name] and Partners

**Bimizza®** is a registered trademark of Morningside Healthcare Ltd

**Mercilon®** is a registered trademark of Organon Pharma (UK) Ltd

1. Organon Pharma (UK) Ltd. Mercilon Tablets. Summary of Product Characteristics. April 2022.   
   Available at: https://www.medicines.org.uk/emc/product/1360 (accessed August 2022);
2. Morningside Healthcare Ltd. Bimizza 150 microgram/20 microgram Tablets. Summary of Product Characteristics. April 2022. Available at: https://www.medicines.org.uk/emc/product/9567 (accessed August 2022);
3. MHRA. UK PAR Bimizza 150 microgram/20 microgram tablets. February 2015. Available at: https://mhraproductsproduction.blob.core.windows.net/docs/33446c8282edba466bfd797be04735e72eb54bca   
   (accessed August 2022).